Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 7Phase 1 5Phase 1/2 3Phase 4 1

Status

Terminated 3Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Thoracic 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × idelalisib × Clear all
NCT03257722 2024-02-28

PIL

Augusta University

Phase 1/2 Terminated
4 enrolled 5 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT03742323 2021-09-05

REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia

PETHEMA Foundation

Phase 1/2 Terminated
6 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01090414 2019-08-28

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

Gilead Sciences

Phase 1/2 Terminated
202 enrolled 18 charts
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡